Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Chemotherapy and Adaptive MR-Guided Radiotherapy to Improve Outcomes in Patients With Esophageal Adenocarcinoma (MERGE): A Phase 1 Dose-Finding Trial

NCT07359443 is registered in ClinicalTrials.gov with UMC Utrecht as lead sponsor.

NCT NCT07359443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07359443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Chemotherapy and Adaptive MR-Guided Radiotherapy to Improve Outcomes in Patients With Esophageal Adenocarcinoma (MERGE): A Phase 1 Dose-Finding Trial
Lead sponsor
UMC Utrecht
Phase
Phase 1
Overall status
Recruiting
Start date
May 21, 2025
Completion date
May 1, 2028
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma - gastroesophageal junction (gej), esophageal adenocarcinoma, esophageal adenocarcinoma (eac)